Eltrombopag ITP denied as not medically necessary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for eltrombopag itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Medical-Necessity Denial for Eltrombopag in ITP

A medical-necessity denial means UHC reviewed a prior-authorization request or a submitted claim and concluded the clinical documentation did not demonstrate that eltrombopag meets the plan's definition of medically necessary care for this patient at this time. For ITP, UHC's clinical coverage policy typically requires evidence of disease severity (documented low platelet counts and associated bleeding risk or symptoms), confirmation that earlier lines of therapy were tried and failed or are clinically contraindicated, and a prescriber attestation that the benefit of treatment outweighs the risk. If the submitted records were incomplete, used inconsistent terminology, or did not address every criterion in the policy, the plan may deny even a clinically appropriate case.

## Why This Denial Is Appealable

Medical-necessity determinations are among the most commonly overturned on appeal because the initial review is often conducted without the full clinical picture. Under ACA §2719, you have the right to internal appeal and, if needed, external review by an independent organization. Under ERISA §503, your plan must provide a full-and-fair review with a written explanation of any uphold. The internal appeal window is generally 180 days from the denial date. External review must typically be requested within 4 months of a final internal denial. An expedited review (72-hour decision) is available for urgent situations.

## Concrete Appeal Steps

1. Read the denial letter carefully — it must list every criterion the plan found unmet. Your appeal must address each one directly. 2. Obtain the UHC clinical coverage policy for eltrombopag or TPO-RAs in ITP — the specific criteria are in that document, not just the denial letter. 3. Submit a structured internal appeal with a point-by-point response to each unmet criterion. 4. Request external review if the internal appeal is upheld — an independent physician reviewer who specializes in hematology will evaluate the case on its clinical merits.

## Documentation to Gather

• Diagnosis confirmation: pathology, bone marrow biopsy (if performed), or hematology evaluation establishing ITP and ruling out secondary causes.
• Platelet count history: a table of serial platelet counts with dates, showing the severity and persistence of thrombocytopenia.
• Prior treatment history: a chronological list of every ITP therapy tried (corticosteroids, IVIG, rituximab, splenectomy if applicable), including start date, duration, response, and reason for discontinuation.
• Bleeding history and symptom burden: clinical notes documenting hemorrhagic episodes, bleeding scores, or functional impairment.
• Prescriber medical-necessity letter: a detailed letter from the treating hematologist explaining why eltrombopag is necessary now, why alternatives are not appropriate, and how the patient's clinical profile meets each criterion in the policy.

## Criteria-Mapping Structure

Create a table that mirrors the UHC policy's requirements:

| UHC Policy Criterion | Chart Evidence Supporting Compliance | |---|---| | Confirmed ITP diagnosis | [Hematology note date + diagnostic findings] | | Platelet count below threshold per policy | [Most recent count date and value from chart] | | Prior corticosteroid trial documented | [Start/end date, response, reason discontinued] | | Additional prior therapy (per policy requirements) | [Therapy name, dates, outcome] | | Prescriber attestation of medical necessity | [Attached letter from Dr. X, dated Y] |

The exact thresholds and line-of-therapy requirements are found in the FDA-approved prescribing label for eltrombopag and in UHC's current published clinical coverage policy. Your documentation must match those specific criteria, not general clinical norms.